- Home
- RLTY vs TMCI Comparison
RLTY vs TMCI Comparison
Compare RLTY & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | TMCI |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.5M | 292.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLTY | TMCI |
|---|---|---|
| Price | $14.92 | $4.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 76.7K | ★ 213.6K |
| Earning Date | 01-01-0001 | 11-06-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $13.34 | $1.17 |
| 52 Week High | $16.41 | $5.25 |
Technical Indicators
Market Signals| Indicator | RLTY | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 65.45 | 57.19 |
| Support Level | $14.04 | $4.03 |
| Resistance Level | $15.92 | $4.88 |
| Average True Range (ATR) | 0.25 | 0.41 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 92.86 | 73.22 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.